Evidence map›Paper›PMID 38333975›Full record

ReviewCurrent medicinal chemistry2025

Application of Nanomedicine in Tumor Targeting Inflammatory Pathway.

Fangshun Tan, Zhuoying Du, Juanjuan Zhong, Yinxin Wu, Jie Mou, Fangnan Zhao, Yuling Liu, Jinlan Chen, Zihan Liang, Yunxi Zhou and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Fangshun TanCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Zhuoying DuCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Juanjuan ZhongCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Yinxin WuCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Jie MouCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Fangnan ZhaoCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Yuling LiuCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Jinlan ChenCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Zihan LiangCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Yunxi ZhouCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Wanling LvCollege of Creative Culture and Communication, Zhejiang Normal University, Jinhua, 321004, China.
Yuxuan CaiCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Bei WangCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Wen XuCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
Chengfu YuanCollege of Basic Medical Science, China Three Gorges University, Yichang, 443002, China.
China Three Gorges University · CNState Administration of Traditional Chinese Medicine of the People's Republic of China · CNZhejiang Normal University · CN

Funding

Central Funds Guiding the Local Science and Technology Development 2020ZYYD016innovational group project of Hubei Province Natural Science Foundation in China 2021CFA015National Natural Science Foundation of China 81974528, 82174035, 82374107, 81773959Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China 2023KZL01
6 · The paper itself

Abstract

Given the threat of ever-growing cancer morbidity, it is a cutting-edge frontier for multiple disciplines to apply nanotechnology in cancer therapy. Nanomedicine is now perpetually influencing the diagnosis and treatment of cancer. Meanwhile, tumorigenesis and cancer progression are intimately associated with inflammation. Inflammation can implicate in various tumor progression via the same or different pathways. Therefore, current nanomedicines exhibit tumor-suppressing function through inflammatory pathways. At present, the comprehensive understanding and research on the mechanism of various nanoparticles in cancer treatment are still in progress. In this review, we summarized the applications of nanomedicine in tumor-targeting inflammatory pathways, suggesting that nanoparticles could be a budding star for cancer therapy.

Indexed as

Antineoplastic AgentsInflammationNanomedicineNanoparticlesNeoplasmsAnimalsHumansAntineoplastic Agentscancerchronic infection.inflammationM1/M2 macrophagemechanismNanomedicinetherapy

Identifiers

PMID38333975
OpenAlexW4391684765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.